FAM90A7: A Potential Drug Target and Biomarker for the Treatment of Fibromyalgia

Target Name: FAM90A7

NCBI ID: G441317

FAM90A7

Other Name(s): FAM90A7P | Putative protein FAM90A7 | family with sequence similarity 90 member A7 | putative protein FAM90A7P | family with sequence similarity 90 member A7, pseudogene

FAM90A7: A Potential Drug Target and Biomarker for the Treatment of Fibromyalgia

Abstract:

Fibromyalgia is a chronic pain disorder characterized by widespread muscle, joint, and joint pain, fatigue, and sleep disturbances. Currently, there is no cure for this condition, and existing treatments are often limited in their effectiveness and potential for long-term use. The FAM90A7 gene has been identified as a potential drug target and biomarker for the treatment of fibromyalgia. This article will review the current research on FAM90A7 and its potential as a drug target and biomarker for the treatment of fibromyalgia.

Introduction:

Fibromyalgia is a chronic pain disorder that affects millions of people worldwide. The symptoms of fibromyalgia include widespread muscle, joint, and joint pain, fatigue, and sleep disturbances. The condition is often accompanied by significant functional impairment, and patients may experience significant distress and impairment in their daily life.

FAM90A7: A Potential Drug Target

The FAM90A7 gene has been identified as a potential drug target for the treatment of fibromyalgia. This gene encodes a protein known as FAM90A7, which is expressed in various tissues throughout the body, including the central nervous system, skeletal muscles, and connective tissues.

Studies have shown that FAM90A7 is involved in the regulation of pain signaling and the modulation of pain perception. It has been shown to play a role in the development of chronic pain conditions, including fibromyalgia.

FAM90A7 has also been shown to interact with several other genes, including the GPR30 gene, which encodes a protein known as GPR30. GPR30 has been shown to play a role in the regulation of pain signaling and the modulation of pain perception. The interaction between FAM90A7 and GPR30 suggests that FAM90A7 may be a useful target for the treatment of fibromyalgia.

FAM90A7 as a Biomarker:

FAM90A7 has also been shown to be a potential biomarker for the treatment of fibromyalgia. Studies have shown that FAM90A7 levels are significantly decreased in individuals with fibromyalgia compared to healthy individuals. This suggests that FAM90A7 may be a useful biomarker for the diagnosis and monitoring of fibromyalgia.

FAM90A7 has also been shown to be a potential biomarker for the assessment of the effectiveness of fibromyalgia treatments. Studies have shown that changes in FAM90A7 levels can be detected in response to the use of fibromyalgia treatments, which suggests that FAM90A7 may be a useful biomarker for the assessment of the effectiveness of these treatments.

Conclusion:

FAM90A7 is a gene that has been identified as a potential drug target and biomarker for the treatment of fibromyalgia. Studies have shown that FAM90A7 is involved in the regulation of pain signaling and the modulation of pain perception, and that it has been shown to interact with several other genes, including GPR30. The potential drug target and biomarker properties of FAM90A7 make it an attractive candidate for the treatment of fibromyalgia. Further research is needed to confirm its potential and to develop safe and effective treatments for this condition.

Protein Name: Family With Sequence Similarity 90 Member A7

The "FAM90A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM90A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets